Lisata Therapeutics and the University of Cincinnati Enters into Sponsored Agreement for Certepetide to Treat Endometriosis
Shots: -
- Lisata entered into a sponsored preclinical research agreement with the University of Cincinnati to investigate Certeptide (cyclic peptide) + Bevacizumab (VEGF inhibitor) as a treatment for Endometriosis
- Under the agreement, Lisata will provide Certepetide and funding while the University of Cincinnati will be conducting the study
- Certepetide selectively targets endometrial tissue by interacting with surface integrin and neuropilin-1 receptors and selectively activates the C-end rule active transport mechanism in a tissue-specific manner and Bevacizumab also showed potential efficacy in treating endometriosis
Ref: Lisata Therapeutics | Image: Lisata Therapeutics
Related News:- Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
